Cargando…
Tocilizumab and Thromboembolism in COVID-19: A Retrospective Hospital-Based Cohort Analysis
Background Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, has been used in patients with coronavirus disease 2019 (COVID-19) as an anti-cytokine agent. IL-6 also plays a complex role in hemostasis and thrombosis. We observed a transient elevation of D-dimer in our patients who received to...
Autores principales: | Chan, Kok Hoe, Patel, Bhavik, Podel, Bishnu, Szablea, Maria E, Shaaban, Hamid S, Guron, Gunwant, Slim, Jihad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220488/ https://www.ncbi.nlm.nih.gov/pubmed/34178527 http://dx.doi.org/10.7759/cureus.15208 |
Ejemplares similares
-
Tranexamic Acid: A Potential Treatment Option for Coronavirus Disease 2019
por: Chan, Kok Hoe, et al.
Publicado: (2020) -
Small Lymphocytic Lymphoma Presenting as a Breast Lump: A Rare Presentation of Non-Hodgkin's Lymphoma
por: Khan, Nazia, et al.
Publicado: (2021) -
COVID-19 Associated Coagulopathy in the Setting of Underlying Malignancy
por: Lim, Su Lin, et al.
Publicado: (2020) -
Persistent Hypercoagulable State in COVID-19: A Case Series of COVID-19 Associated Pulmonary Embolism
por: Chan, Kok Hoe, et al.
Publicado: (2021) -
Epstein-Barr Virus-Positive Primary Diffuse Large B-cell Lymphoma of the Colon in a Patient With Human Immunodeficiency Virus
por: Bethel, Nyan A, et al.
Publicado: (2022)